Table 1 The comparison of clinical and laboratory parameters between study groups at baseline and the end of study.

From: The Effect of Strict Volume Control Assessed by Repeated Bioimpedance Spectroscopy on Cardiac Function in Peritoneal Dialysis Patients

 

Baseline

12 months

TA-OH/ECW <15%

(n = 120)

TA-OH/ECW ≥15%

(n = 31)

p value

TA-OH/ECW <15%

(n = 120)

TA-OH/ECW  15%

(n = 31)

p value

Age

53.5 ± 12.8

55.8 ± 9.0

0.342

   

Sex (male) (%)

66 (55.0)

16 (51.6)

0.736

   

BMI (Kg/m2)

24.5 ± 3.4

23.9 ± 4.0

0.419

   

DM (%)

43 (35.8)

26 (83.9)

<0.001

   

Hypertension (%)

96 (80.0)

26 (83.9)

0.626

   

Cause of ESRD (%)

  

0.001

   

    DM (%)

38 (31.7)

22 (71.0)

    

    Hypertension (%)

39 (32.5)

3 (9.7)

   

    CGN (%)

12 (10.0)

2 (6.5)

   

    Others/Unknown (%)

31 (25.8)

4 (12.9)

    

PD duration (months)

11.8 ± 21.0

11.3 ± 19.0

0.909

   

D/P Cr at 4-hr PET

0.61 ± 0.12

0.67 ± 0.16

0.037

0.60 ± 0.11

0.66 ± 0.13

0.024

No. of anti-hypertensive agents

2.0 ± 1.5

2.7 ± 1.6

0.025

1.3 ± 1.5

2.0 ± 1.4

0.008

Urine output (L/day)

1.00 ± 0.47

1.24 ± 1.71

0.444

0.83 ± 0.48

0.81 ± 0.63

0.855

Systolic BP (mmHg)

132.1 ± 25.6

139.7 ± 24.8

0.143

133.6 ± 19.7

142.0 ± 25.8

0.100

Diastolic BP (mmHg)

79.4 ± 13.2

76.2 ± 11.0

0.220

79.7 ± 10.7

77. 8 ± 11.0

0.377

Pulse pressure (mmHg)

52.7 ± 19.0

63.5 ± 19.3

0.006

53.9 ± 15.4

64.2 ± 18.9

0.002

Laboratory findings

Hemoglobin (g/dL)

11.1 ± 1.2

10.8 ± 1.5

0.241

11.1 ± 1.6

10.3 ± 1.3

0.029

Glucose (mg/dL)

122.1 ± 56.7

159.4 ± 89.7

0.034

128.1 ± 70.1

153.2 ± 77.6

0.084

Serum Creatinine (mg/dL)

8.1 ± 2.7

7.5 ± 3.1

0.289

9.5 ± 3.4

9.1 ± 3.3

0.471

Serum Albumin (g/dL)

3.7 ± 0.4

3.3 ± 0.5

<0.001

3.7 ± 0.4

3.4 ± 0.5

<0.001

Echocardiographic parameters

LA diameter (mm)

38.2 ± 6.2

40.8 ± 7.2

0.052

36.7 ± 6.1

39.4 ± 6.7

0.036

LA volume (ml)

48.3 ± 20.8

51.5 ± 19.4

0.628

45.8 ± 22.9

49.4 ± 22.4

0.477

LVESd (mm)

32.9 ± 9.7

34.1 ± 6.9

0.512

31.6 ± 10.6

34.5 ± 9.4

0.165

LVEDd (mm)

50.2 ± 11.1

51.1 ± 9.5

0.676

48.7 ± 11.4

50.7 ± 8.5

0.359

LV mass index (g/m2)

128.6 ± 69.9

140.4 ± 61.9

0.395

121.1 ± 56.1

120.1 ± 46.9

0.926

ESV (ml)

38.5 ± 21.7

39.0 ± 18.6

0.904

32.2 ± 15.1

37.5 ± 18.6

0.107

EDV (ml)

101.8 ± 41.0

100.7 ± 35.8

0.885

83.9 ± 31.7

93.7 ± 34.7

0.145

EF (%)

62.8 ± 10.1

60.0 ± 7.8

0.155

61.6 ± 6.0

58.8 ± 7.9

0.034

e′ velocity (cm/sec)

5.7 ± 2.8

3.7 ± 2.9

0.001

5.9 ± 4.7

3.7 ± 2.6

0.010

E/A

0.88 ± 0.44

0.77 ± 0.22

0.047

0.88 ± 1.2

0.67 ± 0.14

0.347

E/e′

11.7 ± 11.1

14.9 ± 6.0

0.131

10.3 ± 4.4

13.3 ± 5.0

0.004

  1. *Abbreviation: BMI, body mass index; BP, blood pressure; CGN, chronic glomerulonephritis; DM, diabetes mellitus; D/P Cr, dialysate/peritoneal fluid creatinine ratio; e′, early diastolic mitral annular tissue velocity; E/A, early diastolic mitral inflow velocity/late diastolic mitral inflow velocity; EDV, end-diastolic volume; E/e′, early diastolic mitral inflow velocity/early diastolic mitral annular tissue velocity, EF, ejection fraction; ESRD, end-stage renal disease; ESV, end-systolic volume; LA, left atrial; LV, left ventricular; LVEDd, left ventricular end-diastolic diameter; LVESd, left ventricular end-systolic diameter; PD, peritoneal dialysis; PET, peritoneal equilibrium test.
Back to article page